Cargando…
Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398101/ https://www.ncbi.nlm.nih.gov/pubmed/28469328 http://dx.doi.org/10.4103/0971-5851.203492 |
| _version_ | 1783230402930933760 |
|---|---|
| author | Rastogi, Sameer Gupta, Vineet |
| author_facet | Rastogi, Sameer Gupta, Vineet |
| author_sort | Rastogi, Sameer |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5398101 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Medknow Publications & Media Pvt Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53981012017-05-03 Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? Rastogi, Sameer Gupta, Vineet Indian J Med Paediatr Oncol Editorial Commentary Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5398101/ /pubmed/28469328 http://dx.doi.org/10.4103/0971-5851.203492 Text en Copyright: © 2017 Indian Journal of Medical and Paediatric Oncology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
| spellingShingle | Editorial Commentary Rastogi, Sameer Gupta, Vineet Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title | Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title_full | Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title_fullStr | Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title_full_unstemmed | Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title_short | Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology? |
| title_sort | eribulin approval in advanced liposarcoma – successful drug or a weaker methodology? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398101/ https://www.ncbi.nlm.nih.gov/pubmed/28469328 http://dx.doi.org/10.4103/0971-5851.203492 |
| work_keys_str_mv | AT rastogisameer eribulinapprovalinadvancedliposarcomasuccessfuldrugoraweakermethodology AT guptavineet eribulinapprovalinadvancedliposarcomasuccessfuldrugoraweakermethodology |